1. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet;Barbui;Leukemia,2018
2. High molecular response rate of polycythemia vera patients treated with pegylated interferon α-2a;Kiladjian;Blood,2006
3. 3. European Medicines Agency. BESREMI® Summary of Product Characteristics. Amsterdam, EMA. Available at https://www.ema.europa.eu/en/documents/product-information/besremi-epar-product-information_en.pdf (no date; accessed 10 November 2023).
4. 4. Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Rossiev V, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Grohmann-Izay B, Hasselbalch HC, Kralovics R, Kiladjian JJ; PROUD-PV Study Group. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol 2020;7:e196-208.
5. 5. Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Empson V, Krejcy K, Hasselbalch H, Kralovics R, Kiladjian JJ. S196: Ropeginterferon alfa-2B achieves patient-specific treatment goals in polycythemia vera: final results from the PROUD-PV/CONTINUATION-PV studies. HemaSphere 2022;6:97-98 (abstract).